Achieved the critical milestone of positive operating cash flow in Q4 2025, validating the strategic thesis of the Greenbrook acquisition through revenue growth and expense discipline. Delivered 23% adjusted pro forma revenue growth driven by record capital shipments and a 28% increase in clinic revenue, reflecting successful integration of the national care delivery network. Realigned the NeuroStar capital sales team to focus on 'TMS-ready' accounts—practices with existing staff and insurance credent ...

Core Insights - Neuronetics, Inc. has appointed Dan Reavers as the new President and CEO, effective March 23, indicating a leadership transition aimed at driving future growth [1] - The company reported strong fourth-quarter results with a 23% adjusted pro forma revenue growth, attributed to the successful integration of Greenbrook and increased treatment volumes [5][17] - Positive operating cash flow was achieved in Q4, marking a significant milestone for the company [6] Financial Performance - Total revenue for Q4 2025 was $41.8 million, an 86% increase from $22.5 million in Q4 2024, primarily due to the inclusion of Greenbrook operations [17] - NeuroStar business revenue was $18.3 million, reflecting a 9% pro forma increase year-over-year [17] - Gross margin decreased to 52% from 66% in the prior year, largely due to the lower margin of Greenbrook's clinic business [19] Operational Highlights - Clinic revenue grew 28% on an adjusted pro forma basis, with a significant increase in the referring provider network, adding 430 new providers in Q4 [6][12] - The company executed over 47,000 physician outreach activities, resulting in a 46% increase in patient referrals [7] - The rollout of SPRAVATO is nearly complete, with 84 clinics now offering the treatment [7] Strategic Initiatives - Neuronetics is focused on expanding its NeuroStar TMS systems market access through new models tailored to customer needs [26][27] - The company aims to address the unmet need for treatment-resistant depression (TRD) patients, with plans to advance collaboration with COMPASS Pathways on COMP360 psilocybin [28][29] - The infrastructure built for SPRAVATO is expected to facilitate the launch of new therapies, enhancing patient access and treatment options [30][31] Future Guidance - For 2026, total revenue is projected to be between $160 million and $166 million, indicating over 9% growth compared to 2025 [22] - The company anticipates strong growth in its clinic business, with double-digit year-over-year increases, while the NeuroStar business is expected to grow in the low to mid-single digits [22] - Operating expenses are expected to be between $100 million and $105 million, with a focus on efficiency improvements [23]

AtaiBeckley Conference Call Summary Company Overview - **Company**: AtaiBeckley (NasdaqGM: ATAI) - **Focus**: Mental health conditions, particularly treatment-resistant depression (TRD) and social anxiety disorder (SAD) [2][3] Key Assets in Development 1. **BPL-003**: - **Type**: Intranasal formulation of mebufotenin (5-methoxy-DMT) - **Indication**: Treatment-resistant depression - **Phase**: Advanced, Phase 2b - **Efficacy**: - 8 mg dose showed superior efficacy compared to 12 mg in a Phase 2b study, with a 6.2-point change on the MADRS score compared to placebo [10][11][12][18] - Comparable efficacy to SPRAVATO with only one dose required [11][12] - Open label extension showed continued improvement and remission rates of about 80% [28][29] 2. **VLS-01**: - **Type**: Oral thin film formulation of DMT - **Indication**: Treatment-resistant depression - **Phase**: Phase 2b, currently ongoing with results expected in the second half of the year [133][153] 3. **EMP-01**: - **Type**: R-enantiomer of MDMA - **Indication**: Social anxiety disorder - **Phase**: Phase 2A, exploratory study showed comparable effects to SSRIs at 6 weeks [168][179] Mechanism of Action - **Psychedelic Compounds**: - All three assets are psychedelics that promote neuroplasticity and alter dysregulated circuits associated with depression and anxiety [8][9] - BPL-003 and VLS-01 are designed for short-duration effects, allowing for rapid patient discharge [31][32] Market Landscape - **Interventional Psychiatry**: - A shift from traditional psychiatry to interventional methods, emphasizing rapid symptom relief [222][226] - SPRAVATO has set a precedent in this space, generating approximately $1.7 billion in revenue last year, with expectations of $3 billion this year [240][241] Competitive Advantage - **Convenience**: - AtaiBeckley's products are designed for shorter treatment durations compared to existing options like SPRAVATO, which requires weekly dosing [252][259] - KOLs (Key Opinion Leaders) suggest a strong preference for AtaiBeckley's products due to reduced time commitment for patients [252][259] Infrastructure and Economics - **Current Treatment Sites**: - Approximately 5,000 to 6,000 sites in the U.S. are equipped to administer treatments, with around 600 sites responsible for 80% of revenue [270][272] - **Economic Model**: - AtaiBeckley aims to optimize clinic operations by allowing multiple patients to be treated in a day, enhancing revenue potential for treatment sites [346][348] Future Outlook - **Regulatory Path**: - Plans for two Phase 3 trials for BPL-003, with a focus on flexibility in dosing for physicians [75][76] - **Market Potential**: - The treatment-resistant depression market is estimated at around 3 million people, with current treatments only reaching about 3% of this population [309][311] Conclusion - AtaiBeckley is positioned to capitalize on the growing field of psychedelics in mental health treatment, with a strong pipeline of products that offer convenience and efficacy compared to existing therapies. The company is focused on addressing significant unmet needs in mental health, particularly in treatment-resistant depression and social anxiety disorder.

Core Viewpoint - Neuronetics, Inc. reported strong preliminary unaudited financial results for Q4 and full-year 2025, highlighting significant revenue growth and positive operating cash flow, indicating robust commercial execution and demand for its NeuroStar systems [2][3][10]. Financial Results Summary Fourth Quarter 2025 - Revenue for Q4 2025 was $41.8 million, representing a 23% increase on an adjusted pro-forma basis and an 86% increase compared to Q4 2024 on an as-reported basis [5][10]. - NeuroStar revenue for Q4 2025 was $18.3 million, up 9% on a pro-forma basis compared to the same period in 2024, with 49 NeuroStar Advanced Therapy systems shipped [5][10]. - Clinic revenue for Q4 2025 was $23.5 million, reflecting a 37% increase on an adjusted pro-forma basis compared to Q4 2024 [6][10]. - The company achieved positive operating cash flow of $0.9 million during Q4 2025 [6][10]. Full Year 2025 - Full-year revenue for 2025 was $149.2 million, a 15% increase on an adjusted pro-forma basis and a 99% increase compared to full-year 2024 on an as-reported basis [7][10]. - NeuroStar revenue for the full year 2025 was $62.2 million, up 0.9% on a pro-forma basis compared to 2024 [7][10]. - Clinic revenue for the full year 2025 was $87.0 million, a 28% increase on an adjusted pro-forma basis compared to 2024 [8][10]. - The company ended 2025 with total cash of $34.1 million, including cash, cash equivalents, and restricted cash [8][10].

Core Insights - Johnson & Johnson (JNJ) reported a revenue of $24.56 billion for the quarter ended December 2025, marking a year-over-year increase of 9.1% and exceeding the Zacks Consensus Estimate of $24.12 billion by 1.84% [1] - The company's earnings per share (EPS) for the same period was $2.46, up from $2.04 a year ago, also surpassing the consensus EPS estimate of $2.43 by 1.05% [1] Financial Performance Metrics - Organic Sales Growth was reported at 7.1%, exceeding the average estimate of 6.1% from four analysts [4] - Sales in Innovative Medicine for Oncology (CARVYKTI) reached $555 million, compared to the estimated $624.42 million, reflecting a significant year-over-year increase of 66.2% [4] - Sales in Innovative Medicine for Neuroscience (SPRAVATO) were $503 million, surpassing the average estimate of $463.39 million, with a year-over-year growth of 69.4% [4] - International sales totaled $10.37 billion, exceeding the average estimate of $10.14 billion, representing an 11.3% year-over-year increase [4] - MedTech sales in Cardiovascular (Electrophysiology) were $1.43 billion, slightly below the average estimate of $1.48 billion, with a year-over-year change of 7.9% [4] - Total sales in Innovative Medicine reached $15.76 billion, above the five-analyst average estimate of $15.42 billion, indicating a year-over-year growth of 10% [4] - Sales for Innovative Medicine in Oncology (IMBRUVICA) were $684 million, slightly above the estimated $669.55 million, but reflecting a decline of 6.4% year-over-year [4] - MedTech sales in Orthopaedics (Trauma) were $813 million, exceeding the average estimate of $795.14 million, with a year-over-year increase of 6.4% [4] - MedTech sales in Orthopaedics (Spine, Sports & Other) reached $756 million, above the estimated $735.66 million, showing a year-over-year growth of 2.9% [4] - Advanced Surgery sales were $1.18 billion, slightly below the average estimate of $1.19 billion, with a year-over-year increase of 2.1% [4] - Sales in Innovative Medicine for Cardiovascular/Metabolism/Other were $249 million, below the average estimate of $266.45 million, reflecting a year-over-year decline of 11.4% [4] - Sales in Innovative Medicine for Pulmonary Hypertension were $1.18 billion, exceeding the average estimate of $1.12 billion, with a year-over-year growth of 8.4% [4] Stock Performance - Johnson & Johnson's shares have returned +6% over the past month, outperforming the Zacks S&P 500 composite, which saw a change of -0.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Cyclerion Therapeutics is pioneering a new therapeutic category in neuropsychiatry, focusing on treatment-resistant depression through precision anesthesia and advanced EEG-guided technology [3] Company Overview - Regina Graul serves as the CEO, President, and Director of Cyclerion Therapeutics, leading the company in its innovative approaches to mental health [1] - Dr. Husseini Manji, a prominent figure in neuroscience and mental health, is an adviser to Cyclerion and has significantly influenced the strategy for the company's lead program, CYC-126 [2] Industry Context - There is a substantial unmet need in the treatment of resistant depression, which Cyclerion aims to address with its novel therapeutic approaches [3]

Core Insights - NRx Pharmaceuticals has made significant progress in advancing its corporate objectives and has entered revenue-generating activities for the first time in 2025 [2] - The company is focusing on two main products: NRX-100 for suicidal depression and NRX-101 for bipolar depression, with both products receiving regulatory designations to expedite their development [3][4] Financial Performance - For the quarter ended September 30, 2025, NRx Pharmaceuticals reported a loss from operations of $4.0 million, an increase from a loss of $3.0 million in the same quarter of 2024, primarily due to increased research and development expenses [14] - The company reported revenue of approximately $240,000 for the first time, driven by the acquisition of Dura Medical, which closed on September 8, 2025 [14] - As of September 30, 2025, the company had approximately $7.1 million in cash and cash equivalents, which would increase to $10.3 million after accounting for a subscription receivable [14][16] Product Development and Regulatory Updates - NRX-100 is being developed through both an NDA under FDA Fast Track designation and an ANDA for a preservative-free ketamine product, with the generic ketamine market estimated at approximately $750 million [3][6] - The NDA for NRX-100 is expected to be completed in Q4 2025, incorporating Real World Efficacy Data from over 60,000 patients [4] - NRX-101 has shown promising Real World Efficacy data, indicating that it can double the antidepressant and anti-suicidal effects of Transcranial Magnetic Stimulation (TMS) [10] Corporate Strategy and Expansion - HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, is expanding its network of interventional psychiatry clinics, with three facilities currently operational in Florida and plans for more by year-end [6][12] - The company is actively pursuing additional acquisitions to enhance its clinic network, with potential revenue from these acquisitions estimated to exceed $20 million annually [15] - NRx Pharmaceuticals is also working on a nationwide expanded access program for NRX-101, allowing physicians to provide the medication at no charge to patients [10]

Core Points - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1] Summary by Categories Technical Requirements - Users are advised to enable Javascript and cookies in their browsers to ensure proper functionality [1] - The presence of ad-blockers can lead to blocked access, necessitating their temporary disablement [1]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $37.3 million, an increase of 101% compared to $18.5 million in Q3 2024, primarily driven by the inclusion of Greenbrook operations following the acquisition [16][19] - On an adjusted pro forma basis, revenue increased by 11% year-over-year [16] - Gross margin decreased to 45.9% from 75.6% in the prior year quarter, mainly due to the lower margin of Greenbrook's clinic business [18][19] - Net loss for Q3 2025 was $9.4 million or $0.13 per share, compared to a net loss of $13.3 million or $0.44 per share in the prior year [19] Business Line Data and Key Metrics Changes - Revenue from Greenbrook clinics was $21.8 million, up 25% on an adjusted pro forma basis compared to the prior year [6][18] - NeuroStar business revenue was $15.5 million, with system revenue at $3.5 million and treatment session revenue at $10.5 million [16][19] - NeuroStar treatment session utilization grew 11% year-over-year, indicating strong demand despite a decrease in treatment session revenue due to customer inventory adjustments [17][18] Market Data and Key Metrics Changes - SPRAVATO volumes increased sequentially in Q3 compared to Q2, with 84 of 89 eligible clinics now offering the therapy [8][18] - The company is optimizing its SPRAVATO offering by adjusting billing methods based on state and payer reimbursement dynamics [8][22] Company Strategy and Development Direction - The company is focused on integrating and optimizing operations post-Greenbrook acquisition, aiming to improve efficiencies and capture full value from combined businesses [5][15] - Strategic partnerships, such as with Elite DNA and Transformations Care Network, are expected to expand NeuroStar's footprint and enhance treatment access [23][24] - The company is committed to operational excellence and cash optimization, with initiatives like self-check-in kiosks and AI integration to improve patient experience and reduce costs [12][13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute on priorities and create value for patients and shareholders, highlighting strong momentum in the Greenbrook integration and operational improvements [15][25] - The company anticipates achieving positive cash flow from operations in Q4 2025, with projected revenue guidance of $40 million to $43 million [20][22] Other Important Information - The company has received additional funding under its existing debt agreement, strengthening its cash position [20] - New York State Medicaid began covering NeuroStar TMS therapy for adults with major depressive disorder, expanding access to over 5 million members [15] Q&A Session Summary Question: What is driving the growth dynamics between Greenbrook and NeuroStar sites? - Management noted that Greenbrook clinics saw nearly 28% growth year-over-year, driven by SPRAVATO and TMS segments, while NeuroStar's treatment utilization increased but did not translate to revenue growth due to inventory adjustments [28][29] Question: What changed regarding gross margin expectations post-Greenbrook merger? - Management explained that the lower gross margin is due to the inclusion of Greenbrook's lower-margin clinic business, while NeuroStar's cost structure remains stable [30][31] Question: Can operational efficiencies be quantified in terms of cost savings? - Management indicated that while specific savings have not been quantified, investments in automation and technology are expected to drive long-term efficiencies [35][38] Question: How is the adolescent indication performing and what role does the provider connection program play? - Management reported an uptick in adolescent patient starts, largely driven by the provider connection network, which has increased awareness among primary care physicians [56][57]

Financial Data and Key Metrics Changes - The company has accelerated its timeline for commercialization by nine to twelve months due to successful enrollment in clinical trials and positive dialogue with the FDA [59][63] - The 26-week data from the O6 trial is now expected to be available in early Q3, which is earlier than previously guided [59] Business Line Data and Key Metrics Changes - The company is preparing for the launch of COMM-360, which is expected to be administered at sites currently delivering SPRAVATO, indicating a smooth transition for existing treatment centers [9][10] - The company has made significant progress in strategic collaborations and market access work to ensure a solid understanding of the marketplace landscape [40][41] Market Data and Key Metrics Changes - The company anticipates that a significant number of the approximately 6,000 interventional psychiatry centers capable of administering multi-hour treatments will be certified to deliver COMM-360 at launch [50][55] Company Strategy and Development Direction - The company is focused on building a strong commercial strategy, including marketing, messaging, and payer discussions, to ensure successful market entry [41][42] - The company is also exploring broader access to treatment beyond interventional psychiatry sites, reflecting a commitment to equitable access [55] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for accelerated timelines and the positive relationship with the FDA, which is crucial for the development of psychedelic treatments [48][63] - The company is preparing for an advisory committee meeting with the FDA and is confident in its data collection and risk-benefit characterization for COMM-360 [52][51] Other Important Information - The company has finalized the protocol for PTSD studies and is looking forward to initiating the first patient in Q1 of the following year [64] - The company is actively engaging with the VA to ensure access to treatments upon approval [26] Q&A Session Summary Question: Selection of specialty pharma partner for patient access - The company has not yet selected a partner but is working on understanding distribution pathways and will narrow down options in the coming months [6][7] Question: Administration of COMM-360 at SPRAVATO sites - Any site delivering SPRAVATO today is expected to be capable of delivering COMM-360 if approved, although some incremental changes may be needed [9][10] Question: FDA engagement and data expectations - The company expects to have another meeting with the FDA after releasing significant data in Q1, which will help align on the plan going forward [15][61] Question: Commercialization preparation for March - The company has pulled forward traditional commercial activities and is ready to engage in payer discussions based on upcoming data [41][42] Question: Change in FDA's tone regarding COMM-360 - The company noted a positive change in tone from the FDA, indicating a supportive relationship while maintaining high standards [48][49] Question: Readiness of SPRAVATO infrastructure for COMM-360 - The company is leveraging existing collaborations to ensure that interventional psychiatry sites are prepared to deliver COMM-360 at launch [55]